Our Approach


We develop and commercialize new medicines to improve the daily lives of those affected by chronic neurologic disorders, including Alzheimer’s disease, Parkinson’s disease (PD), multiple sclerosis and epilepsy.

We have pioneered a unique platform to develop medicines by:

  • discovering insights about the underlying temporal patterns of disease activity and drug response;
  • identifying known drugs with potential activity in the disease and synchronize the blood levels needed in the body to match the underlying disease activity pattern; and
  • developing new medicines that match the release of the drug to the synchronized blood profile, first as single agents then in fixed-dose combinations.

Based on this platform, we have developed a portfolio of Chrono-Synchronous Therapies (CSTs) to address chronic neurologic disorders. Our business strategy is to continue to discover, develop and commercialize new treatment solutions for patients independently or in collaboration with partners.